<DOC>
	<DOCNO>NCT02669732</DOCNO>
	<brief_summary>The objective study evaluate change insulin secretory capacity patient type 2 diabetes mellitus determine hyperglycemic clamp 28-day oral administration DS-8500a 75 mg placebo-controlled , 2 × 2 crossover study . In addition , safety regimen examine study .</brief_summary>
	<brief_title>An Exploratory Study DS-8500a Beta Cell Function Using Hyperglycemic Clamp</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients age ≥ 20 year time inform consent Japanese patient type 2 diabetes Patients HbA1c ≥ 7.0 % &lt; 9.0 % Patients type 1 diabetes mellitus history diabetic coma , precoma , ketoacidosis Patients receive require treatment insulin Patients body mass index ( BMI ) &lt; 18.5 kg/m2 ≥ 35.0 kg/m2 Patients clinically evident renal impairment ( estimate glomerular filtration rate [ eGFR ] &lt; 45 mL/min per 1.73 m2 ) clinically significant renal disease Patients fast plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Adult</keyword>
	<keyword>Developmental Phase II</keyword>
</DOC>